GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rule 8.3- CARECAPITAL GROUP PLC

29 May 2009 16:25

RNS Number : 0663T
Amarate Limited
29 May 2009
 



  FORM 8.3

DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE 

(Rule 8.3 of the Takeover Code)

1. KEY INFORMATION

Name of person dealing  (Note 1)

AMARATE LIMITED

Company dealt in

CARECAPITAL GROUP PLC

Class of relevant security to which the dealings being disclosed relate (Note 2)

1P ORDINARY

Date of dealing

MAY 29, 2009

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long

Short

Number (%)

Number (%)

(1) Relevant securities 

1,395,834   1.82%

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

1,395,834 1.82%

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

Number (%)

Number (%)

(1) Relevant securities 

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

(c) Rights to subscribe (Note 3)

Class of relevant security:

Details

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale

Number of securities

Price per unit (Note 5)

(b) Derivatives transactions (other than options)

Product name, 

e.g. CFD

Long/short (Note 6)

Number of securities (Note 7)

Price per unit (Note 5)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise

price 

Type, e.g. American, European etc.

Expiry 

date

Option money

paid/received per unit (Note 5) 

(ii) Exercising

Product name, e.g. call option

Number of securities 

Exercise price per unit (Note 5)

(d) Other dealings (including new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Transfer (receipt) for nil consideration

Receipt of 1,395,834 1p ordinary shares for nil consideration 

0

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

NONE

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure

MAY 29, 2009

Contact name

Andrew Holdsworth

Telephone number

+41 58 705 3404

If a connected EFM, name of offeree/offeror with which connected

If a connected EFM, state nature of connection (Note 10)

Notes

The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETBUGDUDDDGGCC
Date   Source Headline
30th Oct 20205:00 pmRNSTotal Voting Rights
26th Oct 20207:00 amRNSEquity fundraise of c.£7.7m
23rd Oct 20202:25 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy: Progress towards commissioning of first LIGHT
19th Oct 20207:00 amRNSInvestor Day Update
8th Oct 20202:06 pmRNSSecond Price Monitoring Extn
8th Oct 20202:00 pmRNSPrice Monitoring Extension
7th Oct 202010:50 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Progress towards commissioning of first LIGHT
6th Oct 20207:00 amRNSReplacement: Grant of LTIP Options
5th Oct 20207:01 amRNSNotice of Investor Day
5th Oct 20207:00 amRNSGrant of LTIP Options
29th Sep 20207:00 amRNSDirectorate Appointment
29th Sep 20207:00 amRNSInterim Results
8th Sep 20207:00 amRNSTechnical Development Update
7th Sep 20207:00 amRNSAppointment of Joint Broker
21st Aug 20207:00 amRNSDraw down from Nerano Pharma debt facility
18th Aug 20204:30 pmRNSDirector/PDMR Shareholding
29th Jul 20202:52 pmRNSResult of AGM and Directorate Changes
2nd Jul 20207:15 amEQSHardman & Co Research : Advanced Oncotherapy (AVO): End-goal fast approaching
29th Jun 20207:01 amRNSFinal Results for the year ended 31 December 2019
29th Jun 20207:00 amRNSStrategic funding partnership and debt facility
17th Jun 20207:00 amRNSHolding(s) in Company
8th Jun 20207:00 amRNSDirectorate Changes and Notice of Results
3rd Jun 20205:30 pmRNSHolding(s) in Company
29th May 20205:00 pmRNSTotal Voting Rights
20th May 20204:30 pmRNSHolding(s) in Company
11th May 20206:01 pmRNSResult of General Meeting, Additional Subscription
21st Apr 20207:00 amRNSNotice of GM and Posting of Circular
9th Apr 20207:30 amRNSFurther re Subscription and Issue of Equity
9th Apr 20207:00 amRNSProposed Subscription to raise c.£15 million
26th Feb 20203:40 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
20th Feb 20207:00 amRNSUHB and AVO to collaborate over LIGHT system
20th Feb 20207:00 amRNSUHB and AVO to collaborate over LIGHT system
17th Feb 202011:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
17th Feb 20207:00 amRNSPurchase of a LIGHT proton therapy system
11th Feb 20207:00 amRNSPartnership with The London Clinic
4th Dec 20197:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Proving the accuracy and superiority of minibeams
4th Dec 20197:00 amRNSTwo-Year Collaborative Research Study
3rd Dec 20195:45 pmRNSHolding(s) in Company
29th Nov 20195:00 pmRNSTotal Voting Rights
28th Nov 201910:15 amRNSHolding(s) in Company
20th Nov 20197:00 amRNSSubscription to raise c.GBP 2.7 million
11th Nov 20199:11 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): FLASH benefits from new US reimbursement
6th Nov 20193:35 pmRNSTotal Voting Rights
10th Oct 20197:00 amRNSChange of Broker
30th Sep 20195:15 pmRNSTotal Voting Rights
30th Sep 20197:00 amRNSFurther re funding for first LIGHT system
30th Sep 20197:00 amRNSHalf-year Report
9th Sep 20194:48 pmRNSExercise of Warrants and Issue of Equity
30th Aug 20195:00 pmRNSTotal Voting Rights
29th Aug 20192:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.